Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448208 · ClinicalTrials.gov registry record
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
A clinical trial of Neuroendocrine Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 11
- Enrollment target
- 1
- Study location
NCT06448208 is a study of Neuroendocrine Tumors that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06448208, a study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new criteria for doctors to use when evaluating these PET scans. Researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. Researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST positron emission tomography (PET) scans
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06448208
The ClinicalTrials.gov registry entry for NCT06448208 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which positron emission tomography (PET) scans is the first listed.
NCT06448208 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06448208 about?
NCT06448208 is a clinical study titled "Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors". People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new crite...
What is the current status of trial NCT06448208?
This trial is currently active not recruiting. The enrollment target is 11 participants. The study started on 2024-06-03. Estimated completion is 2026-06.
What conditions does trial NCT06448208 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT06448208?
The interventions under investigation include: positron emission tomography (PET) scans (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06448208?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06448208 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.